Top Markets
Coin of the day
Cadrenal Therapeutics, Inc. Common Stock Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. Common Stock

CVKD
Rank in Stocks #33959
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise... Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Share Price
$1.83
Last synced: 2026-08-14
Market Cap
$6.53M
Change (1 day)
-1.61%
Change (1 year)
-85.57%
Country
US
Trade Cadrenal Therapeutics, Inc. Common Stock (CVKD)

Category

P/B ratio for Cadrenal Therapeutics, Inc. Common Stock (CVKD)
P/B ratio as of 2026 TTM: 0
According to Cadrenal Therapeutics, Inc. Common Stock latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Cadrenal Therapeutics, Inc. Common Stock from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE